Last reviewed · How we verify
Urokinase and Dornase alfa
Urokinase and Dornase alfa is a Small molecule drug developed by Azienda Ospedaliera di Padova. It is currently in Phase 2 development.
At a glance
| Generic name | Urokinase and Dornase alfa |
|---|---|
| Sponsor | Azienda Ospedaliera di Padova |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dornase Alfa and Urokinase for Kids With Pleural Empyema (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Urokinase and Dornase alfa CI brief — competitive landscape report
- Urokinase and Dornase alfa updates RSS · CI watch RSS
- Azienda Ospedaliera di Padova portfolio CI
Frequently asked questions about Urokinase and Dornase alfa
What is Urokinase and Dornase alfa?
Urokinase and Dornase alfa is a Small molecule drug developed by Azienda Ospedaliera di Padova.
Who makes Urokinase and Dornase alfa?
Urokinase and Dornase alfa is developed by Azienda Ospedaliera di Padova (see full Azienda Ospedaliera di Padova pipeline at /company/azienda-ospedaliera-di-padova).
What development phase is Urokinase and Dornase alfa in?
Urokinase and Dornase alfa is in Phase 2.